XML 145 R99.htm IDEA: XBRL DOCUMENT v3.24.0.1
Principal changes in the scope of consolidation in 2022 and 2021 - Additional Information (Details)
€ / shares in Units, $ / shares in Units, € in Millions, $ in Millions
 8 Months Ended 11 Months Ended 12 Months Ended
Jun. 17, 2022
EUR (€)
May 10, 2022
EUR (€)
€ / shares
shares
May 03, 2022
Mar. 17, 2022
EUR (€)
Dec. 03, 2021
EUR (€)
Nov. 09, 2021
EUR (€)
Oct. 01, 2021
EUR (€)
Apr. 29, 2021
EUR (€)
Apr. 16, 2021
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Feb. 08, 2022
EUR (€)
Feb. 08, 2022
USD ($)
Nov. 09, 2021
USD ($)
$ / shares
Sep. 14, 2021
EUR (€)
Sep. 14, 2021
$ / shares
Aug. 03, 2021
$ / shares
Apr. 09, 2021
EUR (€)
Apr. 09, 2021
USD ($)
Apr. 08, 2021
EUR (€)
Apr. 08, 2021
USD ($)
Nov. 02, 2020
€ / shares
shares
Jun. 23, 2020
Disclosure of detailed information about business combination [line items]                                                    
Net cash flow on acquisition [1]                       € 3,870 € 992 € 5,594                        
Net sales                       43,070 42,997 37,761                        
Exceptional supplementary dividends recognised as distributions to owners of parent [2]                         793                          
Investments accounted for using the equity method                   € 677 € 677 424 677 250                        
Other gains, (losses) and litigation                       (38) (370) (5)                        
Tax expense (income)                       (1,602) (2,006) (1,558)                        
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax [3]                       € 42 134 42                        
Provision for decommissioning, restoration and rehabilitation costs                                                    
Disclosure of detailed information about business combination [line items]                                                    
Other provisions   € 14                                                
Regulatory compliance costs                                                    
Disclosure of detailed information about business combination [line items]                                                    
Other provisions   € 15                                                
EUROAPI                                                    
Disclosure of detailed information about business combination [line items]                                                    
Proportion of ownership interest in associate (in percent)                   30.10%   29.80%                            
Ownership interest in subsidiary, minimum holding period   2 years                                                
Investments accounted for using the equity method                   € 413 413   413                          
EUROAPI                                                    
Disclosure of detailed information about business combination [line items]                                                    
Exceptional supplementary dividend proposed, percentage of share capital       58000000.00%                                            
Exceptional supplementary dividend, percentage of share capital   58.00% 58.00%                                              
Number of shares received (in shares) | shares   1                                                
Special distribution, number of shares converted (in shares) | shares   23                                                
Special distribution, percentage of share capital distributed   57.88%                                                
Net sales                           486                        
Decrease through loss of control of subsidiary, net assets   € 1,227                                                
Decrease through loss of control of subsidiary, intangible assets and goodwill   € 164                                                
Weighted average share price (in EUR per share) | € / shares   € 14.58                                                
Net foreign exchange loss   € 35                                                
Other gains, (losses) and litigation   3                                                
Tax expense (income)   111                                                
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax   € 101                     101                          
EUROAPI | Manufacture and supply collaboration agreement                                                    
Disclosure of detailed information about business combination [line items]                                                    
Collaboration agreement, period after loss of control             5 years                                      
Collaboration agreement, annual net sales target             € 300                                      
Collaboration agreement, commitment amount                   € 1,100 1,100   1,100                          
EUROAPI | EPIC BPIFrance                                                    
Disclosure of detailed information about business combination [line items]                                                    
Percentage of voting equity interests divested 12000000.00%     12000000.00%                                            
Consideration transferred, maximum amount € 150     € 150                                            
Consideration transferred, valuation period       30 days                                            
Attributable to equity holders of Sanofi                                                     
Disclosure of detailed information about business combination [line items]                                                    
Exceptional supplementary dividends recognised as distributions to owners of parent [2]                         € 793                          
Amunix Pharmaceuticals, Inc                                                    
Disclosure of detailed information about business combination [line items]                                                    
Cash transferred                             € 970                      
Commitments related to milestone payments, business combinations | $                               $ 225                    
Contingent consideration recognised as of acquisition date                             156                      
Net cash flow on acquisition                     € 852                              
Identifiable intangible assets recognised as of acquisition date                             € 493                      
Kymab                                                    
Disclosure of detailed information about business combination [line items]                                                    
Cash transferred                                             € 973 $ 1,100    
Net cash flow on acquisition                           932                        
Commitments related to milestone payments for projects under collaboration agreements | $                                               $ 350    
Identifiable intangible assets recognised as of acquisition date                                             € 965      
Kiadis                                                    
Disclosure of detailed information about business combination [line items]                                                    
Net cash flow on acquisition                           326                        
Identifiable intangible assets recognised as of acquisition date               € 339                                    
Number of shares included in public offer (in shares) | shares                                                 61,000,000  
Purchase price per share (in euro/usd per share) | € / shares                                                 € 5.45  
Proportion of issued and outstanding share capital tendered into the public offer                 95.03%                                  
Financial interest in principal fully consolidated companies               97.39%                                    
Percentage of share capital owned (in percent)                   1.0000 1.0000   1.0000                          
Tidal Therapeutics                                                    
Disclosure of detailed information about business combination [line items]                                                    
Cash transferred                                         € 136 $ 160        
Net cash flow on acquisition                           135                        
Commitments related to milestone payments for projects under collaboration agreements | $                                           $ 310        
Identifiable intangible assets recognised as of acquisition date                                         € 130          
Translate Bio                                                    
Disclosure of detailed information about business combination [line items]                                                    
Net cash flow on acquisition                           € 2,333                        
Identifiable intangible assets recognised as of acquisition date                                   € 396                
Purchase price per share (in euro/usd per share) | $ / shares                                     $ 0.38 $ 0.38            
Investments, ownership percentage                                                   5.00%
Kadmon                                                    
Disclosure of detailed information about business combination [line items]                                                    
Net cash flow on acquisition           € 1,575                                        
Identifiable intangible assets recognised as of acquisition date           € 1,739                                        
Purchase price per share (in euro/usd per share) | $ / shares                                 $ 9.50                  
Estimated purchase price on a fully-diluted basis | $                                 $ 1,900                  
Origimm Biotechnology GmbH                                                    
Disclosure of detailed information about business combination [line items]                                                    
Cash transferred         € 55                                          
Net cash flow on acquisition         50                                          
Commitments related to milestone payments for projects under collaboration agreements         95                                          
Identifiable intangible assets recognised as of acquisition date         € 55                                          
[1] This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2023, it includes the net cash outflow on the acquisitions of Provention Bio and QRIB (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.2.1.). For 2021, it includes the net cash outflows on the acquisitions of Kymab, Kiadis, Tidal, Translate Bio, Kadmon and Origimm (see Note D.2.2.).
[2] This amount includes the valuation of the shares distributed as a dividend in kind, at a price of €14.58 per share, as of May 10, 2022 (see note D.2.1.).
[3] For 2022, this line item includes the net cash inflows (before taxes) of €101 million on the divestment of EUROAPI (see Note D.2.1.).